Haploidentical hematopoietic stem cell transplantation in hematologic malignancies with G-CSF mobilized bone marrow plus peripheral blood stem cells grafts without T cell depletion: a single center report of 29 cases

References

• Guinan EC, Boussiotis VA, Neuberg D, . Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999;340:1704–1714.
   PubMed Web of Science ®Google Scholar
• Goldman FD, Rumelhart SL, DeAlacron P, . Poor outcome in children with refractory/relapsed leukemia undergoing bone marrow transplantation with mismatched family member donors. Bone Marrow Transplant 2000;25:943–948.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Lang P. The history and future prospective of haplo-identical stem cell transplantation. Cytotherapy 2008;10(5): 443–451.
   PubMed Web of Science ®Google Scholar
• Ji SQ, Chen HR, Wang HX, . G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant 2002; 30:861–866.
   PubMed Web of Science ®Google Scholar
• Ji SQ, Chen HR, Yan HM, . Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant 2005;36:349–354.
   PubMed Web of Science ®Google Scholar
• Wang HX, Yan HM, Duan LN, . Haploidentical hematopoietic stem cell transplantation in children hematologic malignancies with G-CSF mobilized marrow grafts without T cell depletion: a single center report of 45 cases. Pediatr hematol Oncol 2009;26:119–128.
   PubMed Web of Science ®Google Scholar
• Lu DP, Dong L, Wu T, . Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006;107:3065–3073.
   PubMed Web of Science ®Google Scholar
• Xu LP, Luo XH, Chang YJ, . High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. Ann Hematol 2009;88(10):1015–1024.
   PubMed Web of Science ®Google Scholar
• Kurokawa T, Ishiyama K, Ozaki J, . Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. Int J Hematol 2010;91(4):661–669.
   PubMed Web of Science ®Google Scholar
• Chen XH, Zhang C, Zhang X, . Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009;15:266–7317
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu K, Xu L, . HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome. Bone Marrow Transplant 2010;45(8):1333–1339.
   PubMed Web of Science ®Google Scholar
• Huang X, Liu D, Liu K, . Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children. Biol Blood Marrow Transplant 2009;15(1 Suppl):91–94.
   PubMed Web of Science ®Google Scholar
• Chen XH, Gao L, Zhang X, . HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation. Blood Cell Mol Dis 2009;43(1):98–104.
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, Huang XJ, Miller JS. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010;16(1 Suppl):S57–S63.
   PubMedGoogle Scholar
• Wu T, Lu DP. Unmanipulated haploidentical blood and marrow transplantation: where we are. Hong Kong Med J 2009;15(3 Suppl 3):27–30.
   PubMedGoogle Scholar
• Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007;17(3):193–197.
   PubMed Web of Science ®Google Scholar
• Xu LP, Liu KY, Liu DH, . The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis. Bone Marrow Transplant 2010;45(6):985–992.
   PubMed Web of Science ®Google Scholar
• Isola LM, Scigliano E, Skerrett D, . A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant 1997;20:1033–1037.
   PubMed Web of Science ®Google Scholar
• Ji S, Chen H, Wang H, . low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells. Chinese Med J 2001;114:191–195.
   PubMed Web of Science ®Google Scholar
• Serody JS, Sparks SD, Lin Y, . Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 2000;6:434–440.
   PubMed Web of Science ®Google Scholar
• Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF) primed allogeneic bone marrow: significantly less graft-vs-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001;98:3186–3191.
   PubMed Web of Science ®Google Scholar
• Nagafuji K, Matsuo K, Teshima T, . Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry. Int J Hematol 2010;91(5):855–864.
   PubMed Web of Science ®Google Scholar
• Ciceri F, Bregni M, Peccatori J. Innovative platforms for haploidentical stem cell transplantation: the role of unmanipulated donor graft. J Cancer 2011;2:339–340.
   PubMed Web of Science ®Google Scholar
• Tuve S, Gayoso J, Scheid C, . Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia 2011;25(5):880–883.
   PubMed Web of Science ®Google Scholar
• Kircher B, Lätzer K, Gastl G, . Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol 2003;134(3):426–430.
   PubMed Web of Science ®Google Scholar
• Chen HR, Ji SQ, Wang HX, . Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp Hematol 2003;31(11):1019–1025.
   PubMed Web of Science ®Google Scholar
• Anasetti C, Martin PJ, Storb R, . Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant 1991;7(5):375–381.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang X, Chen XH, . Factors influencing engraftment in HLA-haploidentical/mismatch related transplantation with combined granulocyte-colony stimulating factor-mobilized peripheral blood and bone marrow for patients with leukemia. Transfuse Apher Sci 2011;44(3):249–255.
   PubMed Web of Science ®Google Scholar
• Guo M, Sun Z, Sun QY, . A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant 2009;15(8):930–937.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Falzetti F, Carotti A, . Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011;117(14):3921–3928.
   PubMed Web of Science ®Google Scholar
• Duan LN, Ding L, Yan HM, . Clinical research on reconstitution of CD4 + CD25 + T cells after haploidentical bone marrow transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010; 18(1):177–180.
   PubMedGoogle Scholar
• Clark FJ, Gregg R, Piper K, . Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004;103(6):2410–2416.
   PubMed Web of Science ®Google Scholar
• Ukena SN, Grosse J, Mischak-Weissinger E, . Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4(+)CD25 (high)CD127 (low/-) regulatory T cells. Ann Hematol 2011;90(2):213–218.
   PubMed Web of Science ®Google Scholar
• Mochizuki K, Kikuta A, Ito M, . Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children. Clin Transplant 2011;25:892–897.
   PubMed Web of Science ®Google Scholar
• Wang Z, Shi BY, Qian YY, . Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. Clin Exp Immunol 2009;155(3):496–503
   PubMed Web of Science ®Google Scholar
• Xu LP, Liu KY, Liu DH, . The inferiority of G-PB to rhG- CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis. Bone Marrow Transplant 2010;45(6):985–992.
   PubMed Web of Science ®Google Scholar